======= MGA =======
== Gene Information ==
* **Official Symbol**: MGA
* **Official Name**: MAX dimerization protein MGA
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23269|23269]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q8IWI9|Q8IWI9]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=MGA&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MGA|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/616061|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerization with MAX. This heterodimerization serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor (By similarity). {ECO:0000250}.
|T-box|
|HLH|
|MLL1 complex|
|negative regulation of G0 to G1 transition|
|regulation of G0 to G1 transition|
|RNA polymerase II activating transcription factor binding|
|cell fate specification|
|protein dimerization activity|
|cell fate commitment|
|RNA polymerase II regulatory region sequence-specific DNA binding|
|negative regulation of cell cycle process|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|negative regulation of cell cycle|
|regulation of cell cycle process|
|negative regulation of transcription by RNA polymerase II|
|regulation of cell cycle|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|DNA binding|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp492|iCRT14 30μM R08 exp492]]|-2.82|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|-2.71|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-2.66|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM on day4 R07 exp420]]|-2.6|
|[[:results:exp400|Senexin-A 25μM R07 exp400]]|-2.58|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-2.54|
|[[:results:exp343|Centrinone 0.5μM R07 exp343]]|-2.5|
|[[:results:exp414|Tozasertib 0.1μM R07 exp414]]|-2.46|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|-2.36|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-2.32|
|[[:results:exp490|Hydroxychloroquine 30μM R08 exp490]]|-2.28|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.2|
|[[:results:exp38|Wortmannin 5μM R00 exp38]]|-2.2|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-2.17|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-2.13|
|[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|-2.04|
|[[:results:exp503|Mitomycin-C 0.06μM R08 exp503]]|-1.96|
|[[:results:exp483|FTY720 3μM R08 exp483]]|-1.92|
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-1.92|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-1.92|
|[[:results:exp472|CI-1040 9.5μM R08 exp472]]|-1.89|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-1.89|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-1.87|
|[[:results:exp485|GSK626616 14μM R08 exp485]]|-1.84|
|[[:results:exp99|NFN1 0.4μM R03 exp99]]|-1.84|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|-1.81|
|[[:results:exp271|CCT251545 0.2μM R06 exp271]]|-1.81|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.8|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-1.79|
|[[:results:exp529|Thimerosal 0.85μM R08 exp529]]|-1.79|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.74|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-1.73|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|-1.7|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|2.5|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|2.57|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.63|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|2.72|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|3.31|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|3.44|
^Gene^Correlation^
|[[:human genes:r:rrm1|RRM1]]|0.483|
|[[:human genes:c:c19orf53|C19orf53]]|0.467|
|[[:human genes:m:mrto4|MRTO4]]|0.412|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 6021
* **Expression level (log2 read counts)**: 7.52
{{:chemogenomics:nalm6 dist.png?nolink |}}